{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:14:14Z","timestamp":1794003254251,"version":"4.8.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jgo.2024.102077","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T10:22:14Z","timestamp":1729246934000},"page":"102077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Corticosteroid therapy in older adults with cancer: Expert recommendations from a task force of the International Society of Geriatric Oncology"],"prefix":"10.1016","volume":"16","author":[{"given":"Rupert","family":"Bartsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Fuereder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois R.","family":"Jornayvaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Olivier","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Migliorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Csajka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Bernadette","family":"Aretin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya M","family":"Wildes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9r\u00e8ne","family":"Dougoud-Chauvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jgo.2024.102077_bb0005","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/annrheumdis-2013-203249","article-title":"EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases","volume":"72","author":"Duru","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jgo.2024.102077_bb0010","first-page":"43","article-title":"Cancer statistics, 2007","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jgo.2024.102077_bb0015","doi-asserted-by":"crossref","unstructured":"2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis - Buckley - 2017 - Arthritis & Rheumatology - Wiley Online Library [Internet]. [cit\u00e9 24 mars 2023]. Disponible sur: doi:https:\/\/doi.org\/10.1002\/art.40137.","DOI":"10.1002\/art.40137"},{"issue":"7","key":"10.1016\/j.jgo.2024.102077_bb0020","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/annonc\/mdu110","article-title":"Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study","volume":"25","author":"Hesketh","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jgo.2024.102077_bb0025","first-page":"32","article-title":"Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed Emesis in patients with breast Cancer: a randomized double-blind study","author":"Roila","year":"2013","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2024.102077_bb0030","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1517\/14740338.2016.1135899","article-title":"The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting","volume":"15","author":"Navari","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"10.1016\/j.jgo.2024.102077_bb0035","first-page":"2971","article-title":"Recommendations for the use of Antiemetics: evidence-based","volume":"17","author":"Gralla","year":"1999","journal-title":"Clin Pract Guidelines JCO"},{"issue":"13","key":"10.1016\/j.jgo.2024.102077_bb0040","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S1470-2045(11)70040-7","article-title":"Polypharmacy in elderly patients with cancer: clinical implications and management","volume":"12","author":"Lees","year":"2011","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2024.102077_bb0045","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/11632400-000000000-00000","article-title":"Evidence-based strategies for the optimization of pharmacotherapy in older people","volume":"29","author":"Topinkov\u00e1","year":"2012","journal-title":"Drugs Aging"},{"issue":"1","key":"10.1016\/j.jgo.2024.102077_bb0050","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12875-017-0642-0","article-title":"Current and future perspectives on the management of polypharmacy","volume":"18","author":"Molokhia","year":"2017","journal-title":"BMC Fam Pract"},{"issue":"5","key":"10.1016\/j.jgo.2024.102077_bb0055","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/theoncologist.7-5-424","article-title":"5-HT3-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile","volume":"7","author":"Goodin","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.jgo.2024.102077_bb0060","doi-asserted-by":"crossref","unstructured":"Navari RM. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. In: Navari RM, \u00e9diteur. Management of Chemotherapy-Induced Nausea and Vomiting: New Agents and New Uses of Current Agents [Internet]. Cham: Springer International Publishing; 2016 [cit\u00e9 21 avr 2023]. p. 107-20. Disponible sur: doi: https:\/\/doi.org\/10.1007\/978-3-319-27016-6_6.","DOI":"10.1007\/978-3-319-27016-6"},{"key":"10.1016\/j.jgo.2024.102077_bb0065","first-page":"53","article-title":"Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study","volume":"3","author":"Hafermann","year":"2011","journal-title":"Drug, Healthcare Patient Safety"},{"issue":"8","key":"10.1016\/j.jgo.2024.102077_bb0070","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/0895-7061(95)00149-J","article-title":"Glucocorticoid-induced hypertension in the elderly relation to serum calcium and family history of essential hypertension","volume":"8","author":"Sato","year":"1995","journal-title":"Am J Hypertens"},{"issue":"11","key":"10.1016\/j.jgo.2024.102077_bb0075","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: a systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.jgo.2024.102077_bb0080","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.afos.2015.07.008","article-title":"The effect of glucocorticoids on bone and muscle","volume":"1","author":"Klein","year":"2015","journal-title":"Osteoporosis Sarcop"},{"issue":"4 Suppl 2","key":"10.1016\/j.jgo.2024.102077_bb0085","first-page":"18","article-title":"Greater risks of chemotherapy toxicity in elderly patients with cancer","volume":"1","author":"Repetto","year":"2003","journal-title":"J Support Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2024.102077_bb0090","first-page":"307","article-title":"Effect of postchemotherapy nausea and vomiting on health-related quality of life","volume":"5","author":"Osoba","year":"1997","journal-title":"Support Care Cancer"},{"issue":"24","key":"10.1016\/j.jgo.2024.102077_bb0095","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1200\/JCO.2014.55.3065","article-title":"Supportive care considerations for older adults with cancer","volume":"32","author":"Naeim","year":"2014","journal-title":"JCO"},{"issue":"8","key":"10.1016\/j.jgo.2024.102077_bb0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11912-016-0535-8","article-title":"Supportive care in older adults with cancer: across the continuum","volume":"18","author":"Koll","year":"2016","journal-title":"Curr Oncol Rep"},{"issue":"8","key":"10.1016\/j.jgo.2024.102077_bb0105","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/annonc\/mds021","article-title":"The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis registry (PEER)","volume":"23","author":"Aapro","year":"2012","journal-title":"Ann Oncol"},{"issue":"27","key":"10.1016\/j.jgo.2024.102077_bb0110","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","article-title":"Delayed nausea and vomiting continue to reduce Patients\u2019 quality of life after highly and moderately Emetogenic chemotherapy despite antiemetic treatment","volume":"24","author":"Bloechl-Daum","year":"2006","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.jgo.2024.102077_bb0115","first-page":"107","article-title":"Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study","volume":"20","author":"Hilarius","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jgo.2024.102077_bb0120","unstructured":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients Ann Oncol [Internet]. [cit\u00e9 21 avr 2023]. Disponible sur: https:\/\/www.annalsofoncology.org\/article\/S0923-7534(19)31641-2\/fulltext."},{"issue":"14","key":"10.1016\/j.jgo.2024.102077_bb0125","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1200\/JCO.2007.10.6583","article-title":"International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients\u2014an analysis of the medical literature","volume":"25","author":"Lichtman","year":"2007","journal-title":"JCO"},{"key":"10.1016\/j.jgo.2024.102077_bb0130","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1037\/0278-6133.26.6.660","article-title":"Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue","volume":"26","author":"Jacobsen","year":"2007","journal-title":"Health Psychol"},{"issue":"1","key":"10.1016\/j.jgo.2024.102077_bb0135","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10549-016-3787-y","article-title":"Prognostic impact of breast cancer subtypes in elderly patients","volume":"157","author":"Bergen","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jgo.2024.102077_bb0140","series-title":"Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management - Launay-Vacher","year":"2007"},{"key":"10.1016\/j.jgo.2024.102077_bb0145","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fphar.2020.00329","article-title":"Patient-related risk factors for chemotherapy-induced nausea and vomiting: a systematic review","volume":"11","author":"Mosa","year":"2020","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jgo.2024.102077_bb0150","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jgo.2012.08.008","article-title":"Efficacy of aprepitant among patients aged 65 and over receiving moderately to highly emetogenic chemotherapy: a meta-analysis of unpublished data from previously published studies","volume":"4","author":"Chapell","year":"2013","journal-title":"J Geriat Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2024.102077_bb0155","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jpainsymman.2013.06.012","article-title":"Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study","volume":"47","author":"Molassiotis","year":"2014","journal-title":"J Pain Symptom Manag"},{"key":"10.1016\/j.jgo.2024.102077_bb0160","article-title":"MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"2024","author":"Herrstedt","year":"2023","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.jgo.2024.102077_bb0165","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1470-2045(23)00628-9","volume":"25","author":"Bajpai","year":"2024","journal-title":"The Lancet Oncology"},{"issue":"7","key":"10.1016\/j.jgo.2024.102077_bb0170","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","article-title":"Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy","volume":"94","author":"Vardy","year":"2006","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.jgo.2024.102077_bb0175","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1634\/theoncologist.2015-0211","article-title":"A prospective multicenter study evaluating secondary adrenal suppression after antiemetic dexamethasone therapy in Cancer patients receiving chemotherapy: a Korean south west oncology group study","volume":"20","author":"Han","year":"2015","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.jgo.2024.102077_bb0180","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.4143\/crt.2015.464","article-title":"A pilot study evaluating steroid-induced diabetes after antiemetic dexamethasone therapy in chemotherapy-treated cancer patients","volume":"48","author":"Jeong","year":"2016","journal-title":"Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.jgo.2024.102077_bb0185","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1634\/theoncologist.2016-0308","article-title":"A prospective observational study on effect of short-term periodic steroid premedication on bone metabolism in gastrointestinal Cancer (ESPRESSO-01)","volume":"22","author":"Nakamura","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.jgo.2024.102077_bb0190","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/CE.S65555","article-title":"Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy","volume":"10","author":"Celio","year":"2015","journal-title":"Core Evid"},{"issue":"10","key":"10.1016\/j.jgo.2024.102077_bb0195","doi-asserted-by":"crossref","first-page":"e1854","DOI":"10.1002\/onco.13851","article-title":"Dexamethasone-sparing regimens with oral netupitant and palonosetron for the prevention of emesis caused by high-dose cisplatin: a randomized noninferiority study","volume":"26","author":"Celio","year":"2021","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.jgo.2024.102077_bb0200","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1186\/s12885-022-10018-3","article-title":"Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant\/palonosetron) in the cisplatin setting: results from a randomized phase 3 study","volume":"22","author":"Celio","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jgo.2024.102077_bb0205","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx216","article-title":"Management of infusion reactions to systemic anticancer therapy: ESMO clinical practice guidelines","volume":"28","author":"Rosell\u00f3","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jgo.2024.102077_bb0210","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2017.05.044","article-title":"Immune checkpoint inhibitors and elderly people: a review","volume":"82","author":"Daste","year":"2017","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.jgo.2024.102077_bb0215","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12979-017-0111-6","article-title":"Interventions to restore appropriate immune function in the elderly","volume":"15","author":"Aspinall","year":"2018","journal-title":"Immun Ageing"},{"key":"10.1016\/j.jgo.2024.102077_bb0220","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.exger.2017.10.002","article-title":"Considerations for successful cancer immunotherapy in aged hosts","volume":"107","author":"Hurez","year":"2018","journal-title":"Exp Gerontol"},{"issue":"8","key":"10.1016\/j.jgo.2024.102077_bb0225","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40266-017-0479-1","article-title":"Cancer immunotherapies: are they as effective in the elderly?","volume":"34","author":"Poropatich","year":"2017","journal-title":"Drugs Aging"},{"issue":"9","key":"10.1016\/j.jgo.2024.102077_bb0230","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.jtho.2019.05.010","article-title":"Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non\u2013small cell lung cancer, including patients aged 70 years or older or with poor performance status (CheckMate 153)","volume":"14","author":"Spigel","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.jgo.2024.102077_bb0235","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1001\/jamaoncol.2021.4960","article-title":"Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study","volume":"7","author":"Nebhan","year":"2021","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.jgo.2024.102077_bb0240","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"36","key":"10.1016\/j.jgo.2024.102077_bb0245","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.jgo.2024.102077_bb0250","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-Cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2024.102077_bb0255","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrurol.2015.254","article-title":"Androgen\u2013glucocorticoid interactions in the era of novel prostate cancer therapy","volume":"13","author":"Narayanan","year":"2016","journal-title":"Nat Rev Urol"},{"issue":"5","key":"10.1016\/j.jgo.2024.102077_bb0260","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.eururo.2014.08.008","article-title":"Corticosteroids and prostate cancer: friend or foe","volume":"67","author":"Geynisman","year":"2015","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.jgo.2024.102077_bb0265","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2217\/fon.13.270","article-title":"The potential detrimental effect of corticosteroids in prostate cancer","volume":"10","author":"Rescigno","year":"2014","journal-title":"Future Oncol"},{"issue":"29","key":"10.1016\/j.jgo.2024.102077_bb0270","doi-asserted-by":"crossref","first-page":"26922","DOI":"10.18632\/oncotarget.4616","article-title":"Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma","volume":"6","author":"Kervo\u00eblen","year":"2015","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.jgo.2024.102077_bb0275","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jgo.2024.102077_bb0280","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.jgo.2024.102077_bb0285","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jgo.2024.102077_bb0290","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an international myeloma working group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jgo.2024.102077_bb0295","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/blood.2020009507","article-title":"Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma","volume":"137","author":"Larocca","year":"2021","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.jgo.2024.102077_bb0300","first-page":"2566","article-title":"How I treat older patients with DLBCL in the frontline setting","volume":"141","author":"Lugtenburg","year":"2023","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.jgo.2024.102077_bb0305","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1182\/blood.V116.21.853.853","article-title":"Rituximab and reduced dose CHOP (R-mini-CHOP) for patients over 80 years with diffuse large B-cell lymphoma (DLBCL) \u2013 Groupe d\u2019Etude des Lymphomes De l\u2019Adulte (GELA) study LNH03-7B","volume":"116","author":"Peyrade","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jgo.2024.102077_bb0310","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/annonc\/mdh432","article-title":"Risk factors for brain relapse in patients with metastatic breast cancer","volume":"15","author":"Slimane","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jgo.2024.102077_bb0315","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1158\/1078-0432.CCR-06-2842","article-title":"A patient perspective on brain metastases in breast cancer","volume":"13","author":"Mayer","year":"2007","journal-title":"Clin Cancer Rese: Off J Am Assoc Cancer Res"},{"issue":"16","key":"10.1016\/j.jgo.2024.102077_bb0320","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s40265-014-0302-9","article-title":"Bevacizumab: a review of its use in advanced cancer","volume":"74","author":"Keating","year":"2014","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jgo.2024.102077_bb0325","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/annonc\/mdr043","article-title":"First-line bevacizumab-containing therapy for breast cancer: results in patients aged \u226570 years treated in the ATHENA study","volume":"23","author":"Biganzoli","year":"2012","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2024.102077_bb0330","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.surneu.2007.06.029","article-title":"The effect of bevacizumab (Avastin) on neuroimaging of brain metastases","volume":"70","author":"Mathews","year":"2008","journal-title":"Surg Neurol"},{"issue":"9","key":"10.1016\/j.jgo.2024.102077_bb0335","first-page":"4061","article-title":"Bevacizumab as front-line treatment of brain metastases from solid tumors: a case series","volume":"33","author":"Zustovich","year":"2013","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.jgo.2024.102077_bb0340","article-title":"Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases","volume":"2","author":"Berghoff","year":"2020","journal-title":"Neuro-Oncol Adv"},{"issue":"5","key":"10.1016\/j.jgo.2024.102077_bb0345","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.ijrobp.2009.12.061","article-title":"Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system","volume":"79","author":"Levin","year":"2011","journal-title":"Intern J Rad Oncol Biol Phys"},{"issue":"33","key":"10.1016\/j.jgo.2024.102077_bb0350","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults","volume":"41","author":"Wen","year":"2023","journal-title":"JCO"},{"issue":"Supplement_5","key":"10.1016\/j.jgo.2024.102077_bb0355","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro-oncology"},{"key":"10.1016\/j.jgo.2024.102077_bb0360","doi-asserted-by":"crossref","unstructured":"Clore JN, Thurby-Hay L. Glucocorticoid-Induced Hyperglycemia. Endocr Pract 2009;15(5):469\u201374.","DOI":"10.4158\/EP08331.RAR"},{"key":"10.1016\/j.jgo.2024.102077_bb0365","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.2337\/dc06-1499","article-title":"Risk of diabetes associated with prescribed glucocorticoids in a large population","volume":"29","author":"Gulliford","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jgo.2024.102077_bb0370","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2147\/DMSO.S330253","article-title":"Management of glucocorticoid-induced hyperglycemia","volume":"15","author":"Shah","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"4","key":"10.1016\/j.jgo.2024.102077_bb0375","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/MAJ.0b013e31828a6a01","article-title":"Glucocorticoid-induced Hyperglycemia","volume":"345","author":"Kwon","year":"2013","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jgo.2024.102077_bb0380","series-title":"Essentials of hospital medicine","first-page":"537","article-title":"Management of Diabetes and Hyperglycemia in hospitalized patients","author":"Skamagas","year":"2013"},{"issue":"1","key":"10.1016\/j.jgo.2024.102077_bb0385","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jhm.391","article-title":"Improved inpatient use of basal insulin, reduced hypoglycemia, and improved glycemic control: effect of structured subcutaneous insulin orders and an insulin management algorithm","volume":"4","author":"Maynard","year":"2009","journal-title":"J Hosp Med"},{"issue":"12","key":"10.1016\/j.jgo.2024.102077_bb0390","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1089\/dia.2014.0115","article-title":"Safe and effective dosing of basal\u2013bolus insulin in patients receiving high-dose steroids for hyper-cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy","volume":"16","author":"Brady","year":"2014","journal-title":"Diabetes Technol Ther"},{"issue":"10","key":"10.1016\/j.jgo.2024.102077_bb0395","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"Recommendations for the management of polymyalgia rheumatica: a European league against rheumatism\/American College of Rheumatology collaborative initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.jgo.2024.102077_bb0400","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/2327-6924.12139","article-title":"Use of nonsteroidal anti-inflammatory drugs in the older adult","volume":"26","author":"Fowler TO","year":"2014","journal-title":"J Am Assoc Nurse Pract"},{"issue":"12","key":"10.1016\/j.jgo.2024.102077_bb0405","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 European league against rheumatism\/American College of Rheumatology Classification Criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"26","key":"10.1016\/j.jgo.2024.102077_bb0410","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jgo.2024.102077_bb0415","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a Meta-analysis","volume":"13","author":"van Staa","year":"2002","journal-title":"Osteoporos Int"},{"issue":"11","key":"10.1016\/j.jgo.2024.102077_bb0420","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1001\/jama.295.11.1300","article-title":"Prevention of osteoporosis associated with chronic glucocorticoid therapy","volume":"295","author":"Heffernan","year":"2006","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jgo.2024.102077_bb0425","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-120-3-199402010-00005","article-title":"Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease","volume":"120","author":"Zelissen","year":"1994","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.jgo.2024.102077_bb0430","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s12603-016-0788-9","article-title":"Vitamin D supplementation in nursing home residents: randomized single cholecalciferol loading protocol vs. individualized loading dose regimen","volume":"21","author":"Delomas","year":"2017","journal-title":"J Nutr Health Aging"},{"issue":"3","key":"10.1016\/j.jgo.2024.102077_bb0435","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.3390\/nu7032044","article-title":"Can we translate vitamin D Immunomodulating effect on innate and adaptive immunity to vaccine response?","volume":"7","author":"Lang","year":"2015","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.jgo.2024.102077_bb0440","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s00198-012-2204-6","article-title":"How important is vitamin D in preventing infections?","volume":"24","author":"Lang","year":"2013","journal-title":"Osteoporos Int"},{"issue":"0102","key":"10.1016\/j.jgo.2024.102077_bb0445","doi-asserted-by":"crossref","DOI":"10.4414\/SMW.2022.w30088","article-title":"Short-term glucocorticoid-related side effects and adverse reactions: a narrative review and practical approach","volume":"152","author":"Noetzlin","year":"2022","journal-title":"Swiss Med Wkly"},{"issue":"7","key":"10.1016\/j.jgo.2024.102077_bb0450","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/ijcp.12822","article-title":"Health benefits of multicomponent training programmes in seniors: a systematic review","volume":"70","author":"Bouaziz","year":"2016","journal-title":"Int J Clin Pract"},{"issue":"7","key":"10.1016\/j.jgo.2024.102077_bb0455","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1001\/jama.282.7.671","article-title":"Glucocorticoid-induced adrenal insufficiency","volume":"282","author":"Krasner","year":"1999","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jgo.2024.102077_bb0460","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.rdc.2015.08.004","article-title":"Infection risk and safety of corticosteroid use","volume":"42","author":"Youssef","year":"2016","journal-title":"Rheum Dis Clin North Am f\u00e9vr"},{"issue":"3","key":"10.1016\/j.jgo.2024.102077_bb0465","doi-asserted-by":"crossref","first-page":"304","DOI":"10.7326\/0003-4819-84-3-304","article-title":"Glucocorticosteroid therapy: mechanisms of action and clinical considerations","volume":"84","author":"Fauci","year":"1976","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.jgo.2024.102077_bb0470","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","article-title":"Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids","volume":"44","author":"Czock","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1016\/j.jgo.2024.102077_bb0475","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S1470-2045(15)00035-2","article-title":"Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials","volume":"16","author":"Rapoport","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2024.102077_bb0480","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/01.HYP.25.3.343","article-title":"Glucocorticoids induce angiotensin-converting enzyme expression in vascular smooth muscle","volume":"25","author":"Fishel","year":"1995","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.jgo.2024.102077_bb0485","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1345\/aph.1H418","article-title":"Effect of Oral corticosteroids on chronic warfarin therapy","volume":"40","author":"Hazlewood","year":"2006","journal-title":"Ann Pharmacother"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406824001838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406824001838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:52:22Z","timestamp":1762033942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406824001838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":97,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1879406824001838"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2024.102077","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Corticosteroid therapy in older adults with cancer: Expert recommendations from a task force of the International Society of Geriatric Oncology","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2024.102077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102077"}}